It’s been claimed that thousands of men with advanced prostate cancer could be denied a new drug following guidance from NICE. NICE initially recommended for NHS funding last October but have reversed this decision. NICE have justified the decision claiming there is a lack of evidence. Enzalutamide extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months. However, it will be banned for patients in England previously treated with abiraterone, another new drug currently used in advanced cases.